2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow NF1: new trials by email Literature Review of NF1 trials Research Report on NF1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 Imlygic - NF1, Neurofibromatosis | Phase 1 | Recruiting | Johns Hopkins University | 10 | 2026-02-01 | 2026-05-08 |
| Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF). Mirdametinib - NF1, Cutaneous Neurofibroma | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2024-02-12 | 2026-04-13 |
Neurofibroma (1) · Neurofibromatoses (1) · Neurofibromatosis 1 (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Syndromes, Hereditary (1) · Nerve Sheath Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Neurocutaneous Syndromes (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Peripheral Nervous System Diseases (1) · Peripheral Nervous System Neoplasms (1)
mirdametinib (1) · talimogene laherparepvec (1)
United States (2)
Carlos Romo, MD (2)